Covaxin, a potential vaccine being prepared by Bharat Biotech against the Coronavirus, is expected to be at least 60 per cent effective and the Hyderabad-based biotechnology company is readying to launch the same in Q2 of 2021, confirmed a top official of the company. The company is aiming for 60 per cent effectiveness of the vaccine but it could also be more, he added.
Bharat Biotech, in collaboration with ICMR, is working on Covaxin. Bharat Biotech commenced Phase III trials of the vaccine earlier this month, with 26,000 volunteers from 25 centres in India participating in it.
It is the largest clinical trial being conducted for a Coronavirus vaccine candidate in India. During the trial, the volunteers will be monitored over the next year to detect any occurrence of Covid-19 disease.
The volunteers will receive two intra-muscular injections approximately 28 days apart. The participants will be randomly assigned 1:1 to receive either two 6 microgram (mcg) injections of Covaxin or two shots of a placebo.
The trial is double-blinded which means that the investigators, the participants and the company will not be aware of who is assigned to which group. Earlier, Covaxin was evaluated in 1,000 subjects during phase 1 and 2 clinical trials.
This post was last modified on 23 November 2020 8:23 am
Thalapathy Vijay's Jana Nayagan's delayed release put the film in a lot of doubt, especially…
SS Rajamouli is known for pushing boundaries with every film he makes. From Magadheera and…
Prashant Kishor and his 'IPAC' team played a crucial role in YS Jagan's landslide victory…
Suriya was going through a series of flops and had to make a comeback with…
Janhvi Kapoor is once again reminding everyone why she's one of Bollywood's most reliable style…
https://youtu.be/QWJyBoBz0uw?si=UJs1XehuVV7SB8_M Satyadev has once again proved why he is regarded as one of the finest…